These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11315979)

  • 1. Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
    Pinna A; Corda L; Carta F
    J Neuroophthalmol; 2001 Mar; 21(1):32-3. PubMed ID: 11315979
    [No Abstract]   [Full Text] [Related]  

  • 2. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical coherence tomography in desferrioxamine ocular toxicity: a place in screening and monitoring?
    Ng WS; Chandra P
    Eye (Lond); 2011 Jul; 25(7):959-61. PubMed ID: 21423137
    [No Abstract]   [Full Text] [Related]  

  • 4. Laryngeal papillomatosis treated by oral zinc sulphate.
    Al-Waiz MM; Al-Nuaimy AA; Aljobori HA; Abdulameer MJ
    Ann Saudi Med; 2006; 26(5):411-3. PubMed ID: 17019091
    [No Abstract]   [Full Text] [Related]  

  • 5. [Retinal pigment epithelium--desferal].
    Roulez F
    Bull Soc Belge Ophtalmol; 2007; (304):59-66. PubMed ID: 17718228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc and chronic leg ulcers: a systematic review of oral zinc in the treatment of chronic leg ulcers.
    Wilkinson E; Hawke C
    J Tissue Viability; 1999 Jan; 9(1):21. PubMed ID: 10480980
    [No Abstract]   [Full Text] [Related]  

  • 7. ZnSO4 treatment of NiSO4-positive patients.
    Santucci B; Cristaudo A; Mehraban M; Valenzano C; Camera E; Picardo M
    Contact Dermatitis; 1999 May; 40(5):281-2. PubMed ID: 10344487
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetic neuropathy and zinc therapy.
    Hayee MA; Mohammad QD; Haque A
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):62-7. PubMed ID: 16967811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yersinia enterocolitica as a cause of intra-abdominal abscess: the role of iron.
    Pallister C; Rotstein OD
    Can J Surg; 2001 Apr; 44(2):135-6. PubMed ID: 11308237
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial.
    Al-Gurairi FT; Al-Waiz M; Sharquie KE
    Br J Dermatol; 2002 Mar; 146(3):423-31. PubMed ID: 11952542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper deficiency myeloneuropathy: a clue to clioquinol-induced subacute myelo-optic neuropathy?
    Schaumburg H; Herskovitz S
    Neurology; 2008 Aug; 71(9):622-3. PubMed ID: 18725588
    [No Abstract]   [Full Text] [Related]  

  • 12. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
    Bene C; Manzler A; Bene D; Kranias G
    Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc sulfate treatment of vocal process granuloma.
    Yilmaz T
    Eur Arch Otorhinolaryngol; 2013 Mar; 270(3):1175. PubMed ID: 23053378
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized, double-blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea.
    Bamford JT; Gessert CE; Haller IV; Kruger K; Johnson BP
    Int J Dermatol; 2012 Apr; 51(4):459-62. PubMed ID: 22435439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vision and hearing during deferoxamine therapy.
    Cohen A; Martin M; Mizanin J; Konkle DF; Schwartz E
    J Pediatr; 1990 Aug; 117(2 Pt 1):326-30. PubMed ID: 2380834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive optic neuropathy and sensorineural hearing loss due to chronic glue sniffing.
    Ehyai A; Freemon FR
    J Neurol Neurosurg Psychiatry; 1983 Apr; 46(4):349-51. PubMed ID: 6842248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic and prophylactic role of oral zinc sulfate in management of recurrent aphthous stomatitis (ras) in comparison with dapsone.
    Sharquie KE; Najim RA; Al-Hayani RK; Al-Nuaimy AA; Maroof DM
    Saudi Med J; 2008 May; 29(5):734-8. PubMed ID: 18454224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A; Khoriaty E; Musallam KM; Taher AT
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract]   [Full Text] [Related]  

  • 20. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.